Welcome to our dedicated page for Metagenomi Therapeutics SEC filings (Ticker: MGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Metagenomi Therapeutics, Inc. (Nasdaq: MGX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a public biotechnology issuer focused on in vivo genome editing and precision genetic medicines. These filings offer detailed information on financial performance, pipeline progress, and key corporate events related to its proprietary gene editing toolbox and programs such as MGX-001 for hemophilia A.
Metagenomi, Inc. files current reports on Form 8-K to announce material events, including quarterly financial results, business updates, and new preclinical data. For example, Form 8-K filings reference press releases that discuss non-human primate data for MGX-001, strategic pipeline prioritization, and corporate presentations. These 8-Ks often furnish exhibits containing full press releases and investor slide decks, which can provide additional scientific and strategic context.
Investors can also review quarterly reports on Form 10-Q and other periodic filings, which the company notes in its press releases, for more comprehensive discussions of research and development activities, collaboration revenue, operating expenses, and risk factors. As an emerging growth company, Metagenomi discloses its status and related accounting elections within these documents.
On Stock Titan, MGX filings are updated from the SEC’s EDGAR system, and AI-powered tools can help summarize lengthy documents such as 10-Qs and 10-Ks, highlight key sections, and clarify technical language. Users can quickly identify items related to in vivo genome editing programs, collaboration agreements, capital allocation, and organizational changes. In addition, Form 4 and other insider transaction reports, when filed, can be reviewed to monitor trading activity by directors and officers.
This page is a central resource for analyzing Metagenomi Therapeutics’ official disclosures, from financial results and pipeline data to governance updates, supporting deeper research into the MGX investment and its genome editing platform.
Metagenomi Therapeutics, Inc. reported that Chief Financial Officer Pamela Wapnick had 2,884 shares of common stock sold at $1.299 per share. According to the footnote, these shares were automatically sold to cover tax withholding on vested restricted stock units and were not a discretionary trade. Following the transaction, she directly holds 208,491 shares.
Metagenomi Therapeutics director and officer Jian Irish reported an automatic share sale tied to tax withholding. On June 5, 2026, 3,737 shares of Metagenomi Therapeutics, Inc. common stock were sold at $1.299 per share to satisfy tax obligations arising from the vesting of restricted stock units granted on April 1, 2024 and April 1, 2025. The filing states this was not a voluntary trade. After the sale, she holds 377,533 shares of common stock directly, and additional shares are held indirectly through family trusts for which she reports but disclaims full beneficial ownership. A footnote also notes that her holdings include 1,500 shares acquired under the company’s employee stock purchase plan on May 29, 2026.
Metagenomi Therapeutics, Inc. officer Matthew Wein reported an automatic sale of 558 shares of common stock at $1.299 per share on June 5, 2026. The shares were sold solely to satisfy tax withholding obligations triggered by the vesting of restricted stock units and were not a voluntary trade.
After this transaction, Wein directly held 126,491 common shares, which includes 1,500 shares acquired through the company’s employee stock purchase plan on May 29, 2026.
Metagenomi Therapeutics, Inc. reported that Brian C. Thomas, Ph.D. resigned from its board of directors effective June 9, 2026, and the company stated his resignation was not due to any disagreement over operations, policies or practices. On the same date, Metagenomi held its 2026 annual stockholder meeting by virtual webcast. A quorum was established with 19,116,207 shares present or represented by proxy out of 37,647,057 shares outstanding and entitled to vote as of the April 13, 2026 record date. Stockholders elected Juergen Eckhardt, M.D., M.B.A. and Eric Bjerkholt, M.B.A. as Class II directors to serve until the 2029 annual meeting, and ratified the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
Metagenomi Therapeutics reported first quarter 2026 results and pipeline progress. Cash, cash equivalents and available-for-sale marketable securities were $140.2 million as of March 31, 2026, and management anticipates this cash runway will support operations through the fourth quarter of 2027.
For the quarter, collaboration revenue was $1.25 million compared with $4.13 million a year earlier. Research and development expenses were $19.3 million versus $25.1 million, and general and administrative expenses were $6.5 million versus $6.8 million. Net loss was $23.1 million, or $0.61 per share, compared with a net loss of $25.0 million, or $0.68 per share, in the prior-year period.
The company highlighted continued progress for MGX-001, its lead hemophilia A program, which it expects to submit for regulatory review, including an IND, in the fourth quarter of 2026, with first-in-human studies planned for 2027. Metagenomi also referenced a publication in Nature Structural & Molecular Biology showcasing its compact CRISPR nuclease MG119-28 and reiterated its strategy to apply its in vivo genome editing platform to hemophilia A and additional genetic and cardiometabolic indications.
Metagenomi Therapeutics, Inc. is asking stockholders to vote at its 2026 virtual annual meeting on June 9, 2026. Stockholders will elect two Class II directors, Juergen Eckhardt and Eric Bjerkholt, to terms running until the 2029 meeting, and ratify PricewaterhouseCoopers LLP as auditor for 2026.
The record date is April 13, 2026, when 37,647,057 common shares were outstanding, each with one vote. The company highlights a staggered three-class board, fully independent key committees, and status as an emerging growth and smaller reporting company, which allows scaled executive compensation disclosure and reduced say‑on‑pay requirements.
Metagenomi Therapeutics director and officer Jian Irish reported equity awards and updated holdings. She received a stock option covering 276,000 shares of common stock at an exercise price of $1.34 per share, expiring on March 31, 2036, with 25% vesting on April 1, 2027 and the rest in 36 monthly installments. She also received 46,000 restricted stock units, 25% of which vest on June 5, 2027, with the remainder vesting in 12 equal quarterly installments. Following these awards, she holds 379,770 shares of common stock directly, and additional shares are held indirectly by the Bruce Irish 2023 Irrevocable Trust FBO Jian Irish and the Jian Irish 2023 Irrevocable Trust, where she disclaims beneficial ownership except to the extent of her pecuniary interest.
Wein Matthew reported acquisition or exercise transactions in this Form 4 filing.
Metagenomi Therapeutics officer Matthew Wein received new equity awards. On April 1, 2026, he was granted options to buy 68,000 shares of common stock at $1.34 per share, expiring on March 31, 2036. The option vests 25% on April 1, 2027, with the rest in 36 equal monthly installments, contingent on continued service. He was also granted 11,000 restricted stock units that begin vesting 25% on June 5, 2027, then in 12 equal quarterly installments. Following these compensation-related grants, his direct common stock holdings total 125,549 shares.